PubMed,
Journal Year:
2024,
Volume and Issue:
65(4), P. E538 - E546
Published: Dec. 1, 2024
Breast
cancer
is
a
major
worldwide
health
concern
that
affects
women
in
both
developed
and
developing
nations.
The
purpose
of
the
study
to
assess
Pakistani
with
breast
cancer's
present
understanding
self-examination
(BSE)
as
well
their
choices
for
traditional
non-conventional
treatment
options.
A
cross-sectional
was
carried
out
two
hospitals'
departments
homeopathic
nutritional
clinics
Lahore,
Pakistan.
data
collected
from
January
June
2023.
total
296
responses
were
obtained.
findings
showed
most
participants
had
little
knowledge
about
BSE
using
multiple
options
without
informing
healthcare
provider.
awareness
crucial
early
detection,
education
risk
factors,
proactive
fitness
management.
Complementary
alternative
medicine
(CAM)
might
cause
problems
when
used
allopathic
medicines,
especially
if
professionals
are
not
adequately
informed
its
concomitant
use.
Discover Oncology,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: Feb. 13, 2025
Cuproptosis,
a
newly
suggested
mechanism
of
controlled
cellular
demise,
which
has
been
extensively
associated
with
aspects
occurrence
and
development
in
breast
cancer.
The
aim
this
study
was
to
conduct
comprehensive
multi-group
bioinformatics
analysis
based
on
the
expression
cuproptosis-related
genes
(CRGs)
identify
novel
cancer
subtypes
guide
clinical
practice.
We
collected
TCGA-BRCA
GSE42568
datasets
investigate
patterns
CRGs
Consensus
cluster
performed
distinct
subtypes.
Subsequently,
an
investigation
carried
out
examine
disparities
between
CRGclusters
through
functional
enrichment
analysis.
Finally,
we
examined
microsatellite
instability,
tumor
mutation
burden,
drug
sensitivity,
infiltration
immune
cells
cell
stemness
across
different
CRGclusters.
identified
two
subtypes,
where
CRGcluster
S2
exhibits
poorer
prognosis
compared
S1.
Moreover,
demonstrated
lower
scores,
higher
index,
increased
burden
relative
S1,
most
frequently
mutated
gene
being
ATP7A.
Notably,
chemotherapy
drugs
such
as
docetaxel,
doxorubicin,
paclitaxel
exhibited
reduced
sensitivity
towards
when
have
that
could
serve
potential
therapeutic
targets
warrant
further
trial
studies
for
Journal of Personalized Medicine,
Journal Year:
2024,
Volume and Issue:
14(5), P. 464 - 464
Published: April 27, 2024
Background:
Cyclin-dependent
kinase
4/6
(CDK4/6)
inhibitors
are
approved
for
advanced
breast
cancer
combined
with
endocrine
therapy
(ET).
The
efficacy
of
CDK4/6
plus
ET
in
hormone
estrogen-positive,
human
epidermal
growth
factor
2-negative
(HR+/HER2−)
early-stage
(esBC)
is
still
to
be
confirmed.
Methods:
We
performed
a
systematic
review
and
meta-analysis
investigate
the
CDK4/6i
esBC.
Main
outcomes
included
invasive
disease-free
survival
(iDFS),
distant
relapse-free
(DRFS),
overall
(OS).
only
phase
III
randomized
controlled
trials.
used
RStudio
version
4.2.3,
we
considered
p
<
0.05
statistically
significant.
Results:
Four
studies
were
selected,
including
14,168
patients,
which
7089
treated
7079
received
monotherapy.
Regarding
patient
characteristics,
6828
(48.2%)
premenopausal.
Compared
alone,
iDFS
rates
(HR
0.81;
95%
CI:
0.67,
0.98;
=
0.034)
significantly
favor
ET.
However,
there
no
significant
differences
DRFS
0.79;
0.58,
1.07;
0.132)
nor
OS
0.96;
0.69,
1.35;
0.829).
Conclusions:
Our
results
show
that
addition
associated
benefit
HR+/HER2−
esBC
patients
iDFS.
More
longer
follow-up
needed
assess
benefits.
Frontiers in Cell and Developmental Biology,
Journal Year:
2025,
Volume and Issue:
13
Published: March 19, 2025
Human
epidermal
growth
factor
receptor
2
(HER2)-low
breast
cancer
is
defined
as
with
an
immunohistochemistry
(IHC)
score
of
1+
or
2+
and
in
situ
hybridisation
(ISH)-negative.
The
traditional
HER2
classification
(negative
positive)
has
limitations,
only
15%–20%
the
population
being
positive
suitable
for
HER2-targeted
therapy.
new
clinical
study,
DESTINY-Breast04,
shows
that
trastuzumab
deruxtecan
(T-DXd)
a
significant
effect
on
advanced
HER2-low
cancers,
accounts
approximately
half
population.
However,
detection
methods
evaluation
criteria
have
not
yet
been
standardised,
toxicity
resistance
mechanisms
associated
T-DXd
therapy
are
still
unclear.
This
article
focuses
these
issues
describes
progress
challenges
T-DXd-related
treatment
patients
low
expression.
Inorganics,
Journal Year:
2025,
Volume and Issue:
13(6), P. 177 - 177
Published: May 23, 2025
In
this
study,
a
novel
4-methylbenzoylhydrazide·dimethyl
sulfoxide·dichloro
platinum(II)
complex
(Pt2)
was
synthesized
and
characterized,
its
anti-tumor
activity
action
mechanism
were
explored.
The
molecular
structure
spatial
configuration
of
the
determined
using
X-ray
diffraction.
results
obtained
fluorescence
spectroscopy
demonstrate
that
can
effectively
bind
to
DNA
affect
properties.
experimental
show
Pt2
exhibited
significant
inhibitory
effects
on
variety
tumor
cell
lines
(MCF-7,
HepG-2,
NCI-H460,
T24,
A549),
IC50
values
lower
than
those
cisplatin
(DDP),
indicating
stronger
activity.
addition,
not
only
significantly
induced
apoptosis
MCF-7
cells
but
also
inhibited
cycle
arrest
at
G2
phase,
with
proportion
G2-phase
as
high
49.47%.
conclusion,
4-methylbenzoylhydrazide
exhibits
good
by
inducing
inhibiting
cycle,
providing
an
important
basis
for
development
platinum-based
drugs.
Journal of Cancer and Tumor International,
Journal Year:
2024,
Volume and Issue:
14(4), P. 162 - 169
Published: Dec. 14, 2024
Background:
Tumor
markers
are
crucial
indicators
for
breast
cancer
treatment
and
follow-up.
Thus,
this
study
attempted
to
explore
the
expression
patterns
of
ER,
PR,
Her2/neu,
Ki67
in
Sudanese
patients.
Methodology:
This
was
a
retrospective
descriptive
analysis
conducted
El-Obeid
city,
Sudan.
Records
190
patients
were
obtained,
including
110
with
malignant
lesions
79
benign
lesions,
from
two
histopathology
laboratories.
Results:
Approximately
37%
ER/PR
positive,
whereas
31%
cases
tested
Her2/neu
classified
as
triple
negative.
Ki-67
exhibited
significant
variability
among
lesions.
Invasive
ductal
carcinoma
(IDC)
highest
estrogen
receptors
(ER)
at
59%,
followed
by
progesterone
(PR)
56%,
HER2
positivity
53.8%.
Conclusion:
Breast
Sudan
prevalent,
characterized
positivity,
triple-negative
status,
elevated
expression.
The
predominant
histological
type
is
invasive
carcinoma.
Women
under
age
45
exhibit
higher
susceptibility
cancer.
A
number
advanced
stages
disease.
advocates
prevention
early
detection
